Patients with hematological malignancies are well nourished prior to allogeneic hematopoietic stem cell transplantation (HSCT). HSCT and associated complications can affect body composition. The study evaluated crosssectionally the prevalence and longitudinally the changes in lean body mass index (LBMI) in HSCT patients. Patients (n ¼ 82) were classified as normal or low LBMI. Logistic regression analyses were used to estimate odds ratios (OR) for low vs normal LBMI, between healthy volunteers and patients; for limited or extensive vs no chronic graft-versus-host-disease (GVHD); and for decreased (Karnofsky o80) vs normal functional status (480). Patients were significantly more likely to have low LBMI at 6, 12 months, 2-3, 4-6 and 46 years than volunteers. In all, 38% of patients were below pre-HSCT LBMI at 4-6 years post-HSCT. Low LBMI was significantly associated with steroid treatment (OR 2.6, confidence intervals (CI) 1.3-5.2, P ¼ 0.008); limited (OR 5.5, CI 1.7-18.5, P ¼ 0.005) or extensive chronic GVHD (OR 20.3, Po0.001); and decreased performance status (Karnofsky scores of p80) (OR 2.7, CI 1.3-5.9, P ¼ 0.01). Patients were more likely to have low LBMI than volunteers. Chronic GVHD and low performance status were associated with low LBMI; thus, complications and/or treatment increase the likelihood of low LBMI.
1,2 However, nutritional consequences after HSCT have not been well studied. Underweight patients are at increased risk of death in the early post-HSCT period, and nonrelapse mortality is greater for extremely underweight or overweight patients. 3, 4 High body mass index (BMI), weight normalized for height, may also affect treatment-related toxicity and mortality. 5 Furthermore, low lean body mass (LBM) has been associated with poor outcome and increased length of hospital stay. 6 Allogeneic HSCT and associated complications, including infections and graft-versus-host-disease (GVHD), can affect body weight and body composition. Immunosuppressive therapy after transplantation has been shown to alter skeletal muscle metabolism. 7 Corticosteroids promote muscle atrophy by increasing the rate of protein catabolism, amino-acid efflux, while simultaneously decreasing the rate of protein synthesis. 8 Thus, treatment and complications following HSCT exert profound negative effects on LBM.
As low LBM is associated with poor outcome, the evaluation of LBM and body fat changes in pre-and post-HSCT patients can aid in adapting nutrition policy, for example, nutrition support in malnutrition and food restriction in obesity. 9 Just as BMI is useful in evaluating the excess or deficit in body weight in individuals of different heights, the lean body mass index (LBMI, kg/m 2 ) and body fat mass index (BFMI, kg/m 2 ) are potentially useful in evaluating body composition parameters by effectively eliminating differences in LBM and body fat with height. 10 Height-independent body composition parameters (LBMI and BFMI) allow height-independent interpretation of nutritional status. Recent advances in body composition measurements include the development of dual-energy X-ray absorptiometry (DXA) for the measurement of LBM and body fat. 11 The aim of this controlled study was to examine crosssectionally, in allogeneic BMT patients, the prevalence of low lean tissue (as assessed by LBMI), and body fat reserves (using BFMI), by follow-up time period and by diagnosis, and to longitudinally evaluate changes in weight, LBMI and BFMI. This is the first 6-year longitudinal study to evaluate body composition parameters in a population of allogeneic BMT patients.
Subjects and methods

Patients
Patients, diagnosed with hematological malignancies, who were treated with allogeneic HSCT, were eligible for inclusion. Those patients who had routine body composition measurements (DXA) between September 1995 and April 2002 were included. This retrospective evaluation includes 192 body composition measurements in 82 patients. Body composition measurements are part of the battery of objective measurements that constitute the routine monitoring of bone mineral status after HSCT. 12 Informed consent was obtained from subjects before being placed on the HSCT waiting list, and the protocol was approved by the Ethics Committee of our institution.
Conditioning regimens
The majority of patients (70) received cyclophosphamide (CY) combined with fractionated total body irradiation (TBI) (CY: 60 mg/kg intravenously (i.v.) day À6 and À5, followed by fractionated TBI (1000 cGy for patients 440 years old or 1200 cGy for younger patients)); 13 7methyl-prednisolone (MP) (54 patients); and 7antithymocyte globulin (ATG) (22 patients). Five patients received a busulfan (BU)-based regimen (BU: 1 mg/kg p.o. every 6 h daily day À7 to À4 and CY: 60 mg/kg i.v. daily days À3 and À2 or with VP16 (60 mg/kg)). Three patients received a reduce-intensity conditioning based on fludarabine 30 mg/m 2 /day for 5 days and four patients other types of conditioning. Patients receiving BU were given clonazepam as seizure prophylaxis. Uroepithelial prophylaxis with hyperhydration and continuous perfusion of mesna was administred during CY infusion and for 24 h after the last dose of CY.
GVHD prophylaxis
The majority of patients received cyclosporine (79 patients)7short-course methotrexate (MTX) (n ¼ 28). 14, 15 The majority of the patients also had complete (n ¼ 51) or partial (n ¼ 15) T-cell depletion in vitro with humanized anti-CD52 (CAMPATH-1M or 1G prior to October 1997 and then CAMPATH-1H produced by Therapeutic Antibody Center, University of Oxford, UK, courtesy of Geoff Hale and Hermann Waldmann). 16 Treatment of established acute GVHD was with high-dose MP; those with GVHD resistant to MP received antithymocyte globulin, either ATGAM (Upjohn, Kalamazoo, MI, USA) or ATGFresenius (Fresenius Medical Care AG, Stans, Switzerland). GVHD was graded according to standard criteria. 17 
Supportive care
Patients were treated at the Bone Marrow 18 In case of neutropenia, foscarnet was given at 90 mg/kg i.v. b.i.d. for 2 weeks and then 90 mg/kg daily or as adjusted for renal impairment for 2 weeks or longer in case of persistent CMV antigenemia. Growth factors were used for druginduced neutropenia and persistent febrile neutropenia. Low-dose heparin (5000 or 10 000 IU i.v. continuous/24 h according to patient weight) was given routinely for hepatic veno-occlusive disease (VOD) prevention. 19 Starting from October 1999, as part of another study, patients also received defibrotide for VOD prophylaxis. 20 
Volunteers
Healthy volunteers (n ¼ 82) from the Geneva area, matched for sex, age and height to the patients, who had DXA measurements, were selected from our database to serve as a control group. 21 
Anthropometric measurements and bioelectrical impedance analysis
Body height was measured to the nearest 0.5 cm and body weight to the nearest 0.1 kg on a balance beam scale. Body composition was measured using whole-body DXA (Hologic QDR-4500 s instrument, Enhanced Whole Body 8.26a software version; Hologic Inc., Waltham, MA, USA). The precision of the measurements is 1.0 and 2.0% for the LBM and FM, respectively. 22, 23 The effective total body radiation dose is 5.2 mSv. 24, 25 The percentage of body fat was measured using the manufacturer's default definition.
LBMI and BFMI (kg/m 2 ) facilitate body composition interpretation by normalizing for differences in height. ) from our healthy subjects (n ¼ 5635). 26 Patients were considered to be at nutritional risk if LBMI was low or if BFMI was high, which corresponds to BMI of o18. 5 
Functional status assessment
Functional status assessments were based on the Karnofsky Performance Status Index, which rates functional status at 10-point intervals from 0 (dead) to 100 (normal). 27 
Statistical analysis
Descriptive statistics (Statview, version 5.0 for PC computers; Abacus Concepts; Piscataway, NJ, USA) were calculated for age, weight, BMI and body composition parameters, and are expressed as mean7standard deviation (x7s.d.). When the data were not normally distributed, the summary descriptive statistics were median and interquartile range. Paired t-tests were used to test differences between volunteers and patients, and between pre-and selected post-HSCT measurements (6, 12 months, 2-3 and 4-6 years) for longitudinal data. w 2 tests were used to evaluate differences in the prevalence of low, normal and high BMI, LBMI and BFMI.
Logistic regression analysis was used to estimate odds ratios (OR) for low, compared to normal LBMI, and high, compared to normal BFMI between controls and patients by time and diagnosis category. ORs were also estimated for limited and extensive, compared to absent chronic GVHD, and decreased (Karnofsky p80), vs normal functional status (Karnofsky 480) in patients. OR with 95% confidence intervals (CI) describe the magnitude of effects for each level of the study variable compared with the reference category.
Results
Cross-sectional study
The diagnoses and treatment of the 82 patients included are shown in Table 1 . The main causes of death were infection (n ¼ 3), relapse or progression of hematological malignancy (n ¼ 12) or transplantation-related causes (n ¼ 3).
There were no significant differences in age, height and weight between patients or volunteers (data not shown). Figure 1 shows the prevalence of low, normal and high BMI, normal and low LBMI and normal and high BFMI in volunteers and patients at pre-and post-BMT. Overall, 21% of measurements in patients fell in the low LBMI category, compared to 5% of volunteers (w 2 ¼ 9.2, P ¼ 0.002). The prevalence of low LBMI was greater at all follow-up periods. This is confirmed by significant ORs of having low, compared to normal LBMI in patients at 6, 12 months, 2-3, 4-6 and 46 years post transplantation, compared to volunteers ( Table 2 ). The prevalence of high BFMI was greater from 2 to 6 years post transplantation than the prevalence of overweight/obese BMI, respectively. Patients were significantly more likely to have high BFMI at 2-3 years post-HSCT only (OR 2.5, CI 1.1-5.7, P ¼ 0.04) than volunteers (data not shown).
Low or high BMI was not associated with time post-HSCT, except for patients who were less likely to have high BMI at 6 months post-HSCT than volunteers (OR 0.4, C 0.1-1.0, P ¼ 0.05). Thus, BMI underestimated the prevalence of low muscle mass or excess body fat.
We further evaluated the likelihood of having low LBMI by diagnosis (data not shown). Patients in all diagnosis categories were significantly more likely to have low LBMI than healthy volunteers. The prevalence of low LBMI was the greatest in non-Hodgkins lymphoma (NHL) and myelodysplastic syndrome (MDS) (38%) and multiple myeloma (MM) (33%) and the lowest in acute myelogenous leukemia (AML) (15%).
Treatment and clinical complications
Patients who received steroid treatment had significantly lower LBMI and BFMI than volunteers. We found a significant association between steroid treatment and low LBMI, adjusted for age (OR 2.9, CI 1.3-6.4, P ¼ 0.008) and high BFMI (OR 0.4, CI 0.2-0.7, Po0.004). Thus, patients who receive steroid treatment were significantly more likely to have low LBMI and less likely to have high BFMI than patients who did not receive steroid treatment. There was no significant association between other chemotherapy treatments (CY, VP-16, BU, thiotepa, MTX, TBI, or T-cell depletion) and low LBMI or high BFMI.
Patients with limited and extensive chronic GVHD had significantly lower LBMI than patients without chronic GVHD. There was a significant association between limited and extensive chronic GVHD, compared to patients without GVHD (Table 3) , and low, compared to normal LBMI. High BFMI was not associated with chronic GVHD.
There was also a significant association between compromised performance status (Karnofsky performance status p80), compared to normal (Karnofsky 480) for low, compared to normal LBMI (Table 3) . 
Discussion
This is the first study to evaluate the prevalence of reduced lean tissue compartment as reflected by LBMI and the long-term effects of HSCT and related complications on body composition. Patients were found to be more likely to have low LBMI, compared to healthy volunteers throughout the follow-up period. Chronic GVHD and low performance status were also associated with low LBMI. In all, 38% of patients do not regain their pre-BMT LBM at 4-6 years post-BMT. Whereas the prevalence of overweight (BMI of 425 kg/m 2 ) was 15% at 6 months post-BMT, it increased to 50% at 2-3 and 4-6 years, which suggests that body fat is restored without a corresponding expansion of LBM.
Situation before and after HSCT
At the time of diagnosis, our study shows that patients are well nourished. Weight and BMI were not significantly different between patients and volunteers. The prevalence of low BMI was similar between volunteers and patients, whereas the prevalence of low LBMI was slightly higher in patients than volunteers at the pre-HSCT evaluation (Figure 1) .
Throughout the post-HSCT period, the prevalence of low LBMI was greater in patients (419%) than in volunteers (5%) and was underestimated by low BMI (o10%) (Figure 1 ). The prevalence of low LBMI or high BFMI was not significantly different between men and women (P40.05). Acute GVHD may have affected the prevalence of low LBMI at 6-months post-BMT. However, there was no significant association between acute GVHD and low LBMI at 6 months. The prevalence of low LBMI was greatest in NHL and MDS (38%) and MM (33%) and lowest in AML (15%). It appears that the presence of high body fat masks the presence of low LBM.
There were no differences in ORs when patients who did not receive TBI were excluded. However, the n for non-TBI patients was too small to evaluate if significant differences in body composition exist between patients who were treated with or without TBI.
Low LBMI does not appear to be the result of suboptimal nutritional support, because body weight and body fat are normal or even increased. It rather suggests that low LBMI is mediated by stress-related factors (treatment, infection) in the early post-BMT period, and that low LBMI in the later phases is due to a lack of muscle accretion that may be due to pituitary or hormonal dysfunction 28 and/or continued metabolic stress. 29, 30 Complications noted throughout the follow-up period in our subjects included infection and sepsis, respiratory and renal insufficiency, hepatitis, chronic fatigue, depression and polyneuropathy, and these may have contributed to the lack of anabolism in the later post-HSCT period. Figure 2 shows that any weight and LBM loss experienced during the immediate post-BMT period is not regained during the first year. Negative nitrogen balance is common in patients in the immediate post-HSCT period 31 as a consequence of negative energy balance due to hyper- metabolism, intestinal losses with diarrhea and catabolic effects on skeletal muscle, initially exerted by the underlying disease, then by conditioning regimens, and subsequently by possible HSCT complications such as infection and GVHD. 29, 30 Whereas weight and BF increased above baseline measurements by 2-3 years post-HSCT, the LBM remained below baseline levels up to 6 years post-BMT, and 38% of patients do not regain their pre-HSCT LBM at 4-6 years post-HSCT. These results suggest that LBM anabolism does not occur as a result of continued secondary effects of disease, complications, treatment or hormonal effects.
Longitudinal data
Effects of treatment
Long-term consequences of TBI have been shown to contribute to pituitary and gonadal dysfunction. 28 Lower BMI were found by Nysom et al 32 in patients with childhood leukemia and lymphomas treated with TBI than in patients without TBI, which suggests that either TBI or more severe delayed side effects after HSCT alter body weight, and possibly body composition. Nyson et al 32 found that cranial irradiation leads to muscle loss and body fat in children. Couto-Silva et al 33 found that children with TBI had lower BMIs at 2 and 5 years post-HSCT than patients who were not treated with TBI. TBI might have contributed to low LBMI reported in this study, since 94% of our patients received pre-HSCT TBI. However, we are unable to determine from our data whether low LBM noted in our patients is due to TBI or due to treatment or secondary complications. Low testosterone levels were not associated with low LBMI, possibly due to testosterone substitution in subjects with low testosterone levels and missing data. Long-term effects of TBI on body composition are likely to be different for adults than for children (eg growth retardation). Further research is necessary to determine effects of TBI on body composition in adults.
Our study showed a significant association between low LBMI and chronic GVHD, which suggests that either the complications of chronic GVHD and/or treatment increased the likelihood of muscle mass depletion (Table 3) . In all, 67% of patients who were diagnosed as chronic GVHD were treated with steroids. Steroid treatment may affect body composition by inducing alterations in substrate oxidation. Our study shows that patients who received steroid treatment were significantly more likely to have low LBMI and less likely to have high BFMI than patients who did not. Horber et al 34 found increased protein oxidation and decreased fat oxidation in healthy volunteers treated with prednisone. Thus, steroid treatment affects body composition. However, the higher ORs noted for limited and extensive GVHD than for steroid treatment suggest that there is an additive effect of GVHD and steroids.
We also found a significant association between performance status, evaluated by Karnofsky performance status, and low LBMI (Table 3) . Patients were 2.7 times more likely to have low LBMI when the functional status was p80 than when rated 480. Only one subject was rated below 60. Thus, low LBM might have contributed to the feeling of fatigue that is frequently reported by HSCT patients, although the feeling of fatigue is likely to be influenced by a number of other factors, including anemia, medications, infection, treatment and other complications.
Body composition measurement as part of patient assessment
Although about 80% of patients fell in the normal or high LBMI category, our study clearly shows that some patients are at risk for LBM depletion. Patients should therefore be monitored for weight and LBM loss. Body composition measurements offer the advantage of determining LBM depletion that might not be detected if masked by an excess body fat. A small percentage (10%) of patients were at risk of obesity and excess body fat after HSCT. Patients should therefore also be monitored for excess weight gain that leads progressively to excess body fat. Furthermore, body composition measurements may help to increase patients' awareness of the relationship between undernutrition, low LBM and fatiguability, and stimulate them to optimize nutritional intake and physical activity.
Study limitations
We were not able to evaluate the data by subgroups to compare the effects of the initial diagnosis, the type of complications (other than GVHD) or treatment (other than corticoids). We were also unable to evaluate the relationship between body composition and the length of hospital stay, because the measurements were not performed during hospital stay and due to too many confounding factors (infection, complications, treatment) that might have influenced body composition changes.
Another limitation of this study is that not all patients were measured at all time points. This was dependent on manpower available in the research facility, and the fact that DXA hardware and software had changed during the course of the study. We only included body composition measurement results from Hologic QDR-4500 s instrument, Enhanced Whole Body 8.26a software version and excluded older versions of DXA hardware or software to avoid introducing a bias in body composition results due to newer compared older software versions. We believe that the results are not jeopardized by this limitation because of the large number of subjects and the duration of the followup. In addition, patients who died were not measured in the terminal phase of the disease; therefore, the deleterious effects of lethal complications and cancer relapse on body composition were not studied. Mortality in this study was 22% (18 of 82 patients included) and low LBM could not be associated with survival.
Conclusions
Patients were more likely to have low LBMI, compared to volunteers throughout the follow-up period. Whereas weight and body fat reserves increased above baseline measurements by 2-3 years post-HSCT, the lean tissue compartment (LBM) remained below baseline levels up to 6 years post-HSCT, and 38% of patients do not regain their pre-HSCT LBM at 4-6 years post-HSCT. Chronic GVHD and low performance status were also associated with low LBMI, which suggests that either the complications of chronic GVDH and/or treatment increased the likelihood of muscle mass depletion. Our study clearly shows that HSCT patients are at risk for LBM depletion. Patients should therefore be monitored for body composition.
